EUVIMEDEUVIMED entdecken
Klinische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Treatment satisfaction and patient reported outcomes among people with opioid use disorder participating in an open‐label, non‐randomised trial of long‐acting injectable buprenorphine treatment in Australian custodial settings

Bethany White iD, Sophia Little iD, Paul S Haber, Jillian Roberts, Erin Nolan, Nicholas Lintzeris iD, Adrian J Dunlop iD

Drug and Alcohol Review · 2025

DOI: 10.1111/dar.14005 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Drug and Alcohol Review, 2025. Verfasst von Bethany White und 6 weiteren Autor:innen. Beteiligte Einrichtung: Edith Collins Centre for Translational Research in Alcohol, Drugs and Toxicology, Sydney Local Health District, Sydney, Australia. Hauptthemen laut MEDLINE: Buprenorphine, Opioid-Related Disorders, Patient Satisfaction, Patient Reported Outcome Measures. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NSW Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

A trial of long‐acting injectable buprenorphine (LAIB) in Australian prisons allowed examination of treatment satisfaction and patient‐reported outcomes.

Methods

UNLOC‐T was a 16‐week non‐randomised open‐label study. Men and women aged ≥18 years with moderate/severe DSM‐5 opioid use disorder currently serving a custodial sentence ≥6 months were recruited. Participants not in opioid agonist treatment (OAT) commenced LAIB ( n = 67); those already stable on oral methadone treatment were recruited to a comparison arm ( n = 62). The Treatment Satisfaction Questionnaire for Medication (TSQM), Patient Satisfaction Visual Analogue Scale (PS‐VAS) and Treatment Burden Questionnaire assessed treatment satisfaction; the Kessler Psychological Distress Scale (K10), 12‐Item Short Form Health Survey (SF‐12) and the Australian Treatment Outcomes Profile (ATOP) measured mental health, physical health and quality of life.

Results

Among participants receiving LAIB, TSQM global satisfaction scores significantly increased from 68.2 (SD 16.6) to 77.0 (SD 18.4) by week 16 ( p = 0.0041), as did satisfaction measured by the PS‐VAS (62.5 [SD 29.2] vs. 79.4 [SD 25.5], p = 0.0005). Statistically significant improvements between baseline and week 16 were also observed for K10, SF‐12 (total) and SF‐12 (mental health) scores. By the end of the study, ‘successful’ treatment outcomes were observed in the ATOP domains of psychological health (84%), physical health (80%) and quality of life (86%). Discussion and Conclusions Participants inducted and stabilised on LAIB reported high treatment satisfaction and improved health and wellbeing. Results suggest LAIB is acceptable to people with opioid use disorder in custody, supporting scaleup of this medication to increase coverage of OAT in these settings. Trial registration: https://www.anzctr.org.au ACTRN12618000942257.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BuprenorphineOpioid-Related DisordersPatient SatisfactionPatient Reported Outcome MeasuresOpiate Substitution TreatmentNarcotic AntagonistsPrisonersHumansMaleFemaleAdultAustraliaMiddle AgedTreatment OutcomeQuality of LifeDelayed-Action PreparationsYoung AdultPrisons

Stichwörter der Autor:innen

long‐acting injectable buprenorphinemedication satisfactionopioid use disorderpatient reported outcomesprison

Substanzen

BuprenorphineDelayed-Action PreparationsNarcotic Antagonists

Autor:innen und Institutionen

  • Edith Collins Centre for Translational Research in Alcohol, Drugs and Toxicology, Sydney Local Health District, Sydney, Australia.
  • Specialty of Addiction Medicine, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
  • Drug & Alcohol Clinical Research & Improvement Network, Sydney, Australia.
  • Justice Health and Forensic Mental Health Network, Sydney, Australia.
  • Drug & Alcohol Clinical Services, Hunter New England Local Health District, Newcastle, Australia.
  • Hunter Medical Research Institute, Newcastle, Australia.

ORCID-Profile: Bethany White, Sophia Little, Nicholas Lintzeris, Adrian J Dunlop

Förderung

  • NSW Health

Zitieren

APA

White, B., Little, S., Haber, P. S., Roberts, J., Nolan, E., Lintzeris, N., & Dunlop, A. J. (2025). Treatment satisfaction and patient reported outcomes among people with opioid use disorder participating in an open‐label, non‐randomised trial of long‐acting injectable buprenorphine treatment in Australian custodial settings. Drug and Alcohol Review. https://doi.org/10.1111/dar.14005

Vancouver

White B, Little S, Haber PS, Roberts J, Nolan E, Lintzeris N, et al. Treatment satisfaction and patient reported outcomes among people with opioid use disorder participating in an open‐label, non‐randomised trial of long‐acting injectable buprenorphine treatment in Australian custodial settings. Drug and Alcohol Review. 2025. doi:10.1111/dar.14005

BibTeX
@article{White2025,
  author = {White, Bethany and Little, Sophia and Haber, Paul S and Roberts, Jillian and Nolan, Erin and Lintzeris, Nicholas and Dunlop, Adrian J},
  title = {Treatment satisfaction and patient reported outcomes among people with opioid use disorder participating in an open‐label, non‐randomised trial of long‐acting injectable buprenorphine treatment in Australian custodial settings},
  journal = {Drug and Alcohol Review},
  year = {2025},
  doi = {10.1111/dar.14005}
}
Kostenlos starten →